Immune Therapy Holdings

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

Retrieved on: 
Tuesday, December 12, 2023

Iskra Reic, Executive Vice President, Vaccines & Immune Therapies, AstraZeneca, said: “This virus-like particle vaccine technology has the potential to transform prevention against severe infectious diseases, including RSV and hMPV.

Key Points: 
  • Iskra Reic, Executive Vice President, Vaccines & Immune Therapies, AstraZeneca, said: “This virus-like particle vaccine technology has the potential to transform prevention against severe infectious diseases, including RSV and hMPV.
  • Icosavax’s lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
  • In Icosavax’s Phase II trial, IVX-A12 showed robust immune responses across RSV and hMPV antibodies, reconfirming previous immunogenicity data seen in the smaller Phase I trial.
  • The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial.

EQS-News: Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

Retrieved on: 
Tuesday, October 17, 2023

The data, therefore, validates the potential of vidofludimus calcium in UC and other inflammatory bowel disease indications.”

Key Points: 
  • The data, therefore, validates the potential of vidofludimus calcium in UC and other inflammatory bowel disease indications.”
    The CALDOSE-1 trial of vidofludimus calcium in moderate-to-severe ulcerative colitis (UC) was a phase 2b, multicenter, randomized, double-blind, placebo-controlled, dose-finding study, including a blinded 10-week induction phase and a blinded 50-week maintenance phase.
  • Similarly, patients treated with vidofludimus calcium achieved dose-linear increases in steroid-free clinical remission, endoscopic healing and microscopic healing.
  • An exploratory statistical analysis showed superiority of the 30 mg vidofludimus calcium treatment group over placebo for both clinical remission (p=0.0358) and endoscopic healing (p=0.0259).
  • Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this trial was found to be safe and well-tolerated.

Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

Retrieved on: 
Monday, October 16, 2023

The data, therefore, validates the potential of vidofludimus calcium in UC and other inflammatory bowel disease indications."

Key Points: 
  • The data, therefore, validates the potential of vidofludimus calcium in UC and other inflammatory bowel disease indications."
  • The CALDOSE-1 trial of vidofludimus calcium in moderate-to-severe ulcerative colitis (UC) was a phase 2b, multicenter, randomized, double-blind, placebo-controlled, dose-finding study, including a blinded 10-week induction phase and a blinded 50-week maintenance phase.
  • Similarly, patients treated with vidofludimus calcium achieved dose-linear increases in steroid-free clinical remission, endoscopic healing and microscopic healing.
  • Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this trial was found to be safe and well-tolerated.

Serotonin Centers Breaks New Ground as Nation's First Human Longevity Franchise

Retrieved on: 
Wednesday, September 8, 2021

"It's time to remove the guesswork that the medical industry had consumers accepting far too long," Casaburi said.

Key Points: 
  • "It's time to remove the guesswork that the medical industry had consumers accepting far too long," Casaburi said.
  • "This revelation led me down a two-year research and development path that is now ready for the masses.
  • I'm excited to share the Serotonin brand with like-minded investors who want to make an impact on human health and life span while seeking a ground-floor opportunity."
  • Those interested in investing in a Serotonin Center can call (800) 737-6866 or go to serotonincenters.com/franchising/ for more information.

Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board

Retrieved on: 
Thursday, June 17, 2021

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease Clinical Advisory Board.

Key Points: 
  • SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease Clinical Advisory Board.
  • The advisory board includes respected researchers and clinicians who are thought leaders in the research and treatment of inflammatory bowel disease (IBD).
  • The advisory board will provide clinical and strategic guidance on Progenitys ingestible therapeutics and diagnostics pipeline, as the company transitions from preclinical to clinical studies.
  • This data will enable the clinical advisory board to refine Progenitys clinical development plan for its lead candidates with clinical trials expected to begin in 2022.

Anti-inflammatory Drugs Market Report 2021 - Global Size, Share, Outlook, and Opportunity Analysis, 2020-2027 with 2019 as the Base Year - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 1, 2021

The "Anti-inflammatory Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anti-inflammatory Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Anti-inflammatory drugs are used in the treatment of acute and chronic diseases with inflammatory etiology.
  • Therapeutic delivery of anti-inflammatory drugs to the target site of action and simultaneously avoiding undesired side effects.
  • Rising incidence of acute and chronic diseases such as arthritis is expected to drive anti-inflammatory drugs market growth.

Aldeyra Therapeutics Announces Development Programs at 2018 Research Day

Retrieved on: 
Tuesday, June 26, 2018

LEXINGTON, Mass., June 26, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced product development programs in systemic inflammatory disease, retinal disease, and cancer at the company's 2018 Research Day.

Key Points: 
  • LEXINGTON, Mass., June 26, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced product development programs in systemic inflammatory disease, retinal disease, and cancer at the company's 2018 Research Day.
  • "We are pleased to announce programs in immune-mediated disease, including inflammatory bowel disease, non-alcoholic steatohepatitis, retinal inflammation, lymphoproliferative immune disease, and cancer."
  • Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases.
  • Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue.